Your browser doesn't support javascript.
loading
Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management.
Heskin, Joseph; Pallett, Scott J C; Mughal, Nabeela; Davies, Gary W; Moore, Luke S P; Rayment, Michael; Jones, Rachael.
Affiliation
  • Heskin J; Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK. Electronic address: j.heskin@nhs.net.
  • Pallett SJC; Royal Defence Medical College, Royal Centre for Defence Medicine, Birmingham, UK.
  • Mughal N; Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.
  • Davies GW; Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.
  • Moore LSP; Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.
  • Rayment M; Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.
  • Jones R; Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.
Lancet ; 399(10319): 21-22, 2022 01 01.
Article in En | MEDLINE | ID: mdl-34973713

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proline / Ritonavir / Viral Protease Inhibitors / COVID-19 Drug Treatment / Lactams / Leucine / Nitriles Limits: Humans Language: En Journal: Lancet Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proline / Ritonavir / Viral Protease Inhibitors / COVID-19 Drug Treatment / Lactams / Leucine / Nitriles Limits: Humans Language: En Journal: Lancet Year: 2022 Document type: Article